arrow
Y

Yasmine Baca

university of california-san diego
H指数:15
被引数:831

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer

II类和III类BRAF突变在结直肠癌中的临床和分子特征

2026-02-260
OAAI
Molecular alteration profiles characterize intraductal carcinoma of the prostate

分子改变特征可表征导管内前列腺癌

Cancer
IF5.1
2026-01-010
PRE
The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer

GR-LEDGF/p75-HSP27轴在前列腺癌中促进了恩杂鲁胺和多西他赛之间的交叉耐药性。

2025-10-090
OAAI
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)

非小细胞肺癌(NSCLC)中获得性EGFR耐药突变的发生率及其分子相关性

2025-04-170
PRE
Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes
2024-12-300
PRE
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting (vol 8, 87, 2024)
2024-05-060
OAAI
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
2024-04-082
OAAI
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
2024-04-011
PRE
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
2023-07-037
OAAI
Pan-cancer analysis of XPO1 R749Q mutations across 217,570 patients reveals association with high tumor mutational burden and therapy resistance
2023-04-040
PRE
Clock Genes in Breast Cancer
2023-03-011
PRE
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
2022-09-169
OAAI